{"filing":{"accession_number":"0001193125-26-307773","cik":"0001671858","ticker":"SPRY","company_name":"ARS Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-17","report_date":null,"primary_document":"d168709d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526307773/d168709d8k.htm"},"events":[{"id":18664,"run_id":16783,"accession_number":"0001193125-26-307773","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses two executive departures: Richard Lowenthal's resignation from the Board of Directors effective immediately on July 15, 2026, and Sarina Tanimoto, M.D. (Chief Medical Officer), ceasing employment under a termination without cause on the same date. While severance and compensatory arrangements are mentioned, the principal disclosed action centers on these two individuals leaving their roles. The departure of a CMO is material to a pharmaceutical company's operations and investor assessment.","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-07-17","form":"8-K","submitted_at":null,"items":[{"id":17542,"accession_number":"0001193125-26-307773","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses two executive departures: Richard Lowenthal's resignation from the Board of Directors effective immediately on July 15, 2026, and Sarina Tanimoto, M.D. (Chief Medical Officer), ceasing employment under a termination without cause on the same date. While severance and compensatory arrangements are mentioned, the principal disclosed action centers on these two individuals leaving their roles. The departure of a CMO is material to a pharmaceutical company's operations and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:04:36.720820+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17542,"accession_number":"0001193125-26-307773","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses two executive departures: Richard Lowenthal's resignation from the Board of Directors effective immediately on July 15, 2026, and Sarina Tanimoto, M.D. (Chief Medical Officer), ceasing employment under a termination without cause on the same date. While severance and compensatory arrangements are mentioned, the principal disclosed action centers on these two individuals leaving their roles. The departure of a CMO is material to a pharmaceutical company's operations and investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-17T20:04:36.720820+00:00","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-07-17"}]}